Did you mean: (Dyslipidemia)?
- Effects of a nutraceutical combination of monacolin, γ-oryzanol and γ-aminobutyric acid on lipid profile and C-reactive protein in mice. [Journal Article]
- AMArch Med Sci 2019; 15(3):792-796
- CONCLUSIONS: We can conclude that a combination of monacolin K 3%, γ-oryzanol, and γ-aminobutyric acid is more effective than monacolin K 3% alone in reducing the negative effects of a HFD in a sample of specific pathogen-free mice.
- Effects of vitamin D supplementation on insulin resistance and dyslipidemia in overweight and obese premenopausal women. [Journal Article]
- AMArch Med Sci 2019; 15(3):598-606
- CONCLUSIONS: Our results support the effect of vitamin D3 supplementation in HOMA-IR and LDL-C improvement in both obese and overweight subjects. Further studies focused on low serum 25(OH)D levels with insulin resistance and dyslipidemia are needed.
- Risk factors of gallbladder polyps formation in East Asian population: A meta-analysis and systematic review. [Journal Article]
- AJAsian J Surg 2019 May 17
- CONCLUSIONS: In conclusion, risk factors of gallbladder polyp formation included male gender, higher BMI, higher waist circumference, higher DBP, higher LDL, lower HDL and positive HBsAg in east Asian population. GBP formation was not correlated with age, hypertension, DM, smoking, drinking, fatty liver, GBS, TC, TG, SBP, ASL and ALT. The mechanism of Dyslipidemias causing GBP needs deeper study in future.
- Development of an Interactive Outcome Estimation Tool for Laparoscopic Roux-en-Y Gastric Bypass in Mexico Based on a Cohort of 1002 Patients. [Journal Article]
- OSObes Surg 2019 May 19
- CONCLUSIONS: We were able to develop an interactive estimation application to provide a population-based guidance for potential outcomes of LRYGB. This might be useful not only for health professionals but also for patients interested in learning potential outcomes in specific circumstances.
- Statins and non-alcoholic fatty liver disease. [Journal Article]
- LILiver Int 2019 May 13
- In April 9 issue, van den Berg EH et al.1 report interesting results on the indication for lipid-lowering treatment in a large cohort with suspected NAFLD within the population-based Lifelines Cohort…
In April 9 issue, van den Berg EH et al.1 report interesting results on the indication for lipid-lowering treatment in a large cohort with suspected NAFLD within the population-based Lifelines Cohort Study. FLI≥60 was used as a proxy of NAFLD and the NAFLD fibrosis score (NFS) to identify NAFLD patients with suspected advanced fibrosis. CVD risk was established by the 2016 ESC/EAS Guidelines for the Management of Dyslipidemias2 . This article is protected by copyright. All rights reserved.
- Adherence to a priori dietary indexes and baseline prevalence of cardiovascular risk factors in the PREDIMED-Plus randomised trial. [Journal Article]
- EJEur J Nutr 2019 May 09
- CONCLUSIONS: Highest adherence to dietary quality indexes, especially Mediterranean-style and PDQS scores, showed marginal associations with lower prevalence of individual and clustered CVRF among elderly adults with metabolic syndrome at high risk of cardiovascular disease.
- [Clinical features of 20 patients with phytosterolemia causing hematologic abnormalities]. [Journal Article]
- ZYZhonghua Yi Xue Za Zhi 2019 Apr 23; 99(16):1226-1231
- CONCLUSIONS: The phenomena of thrombocytopenia/ stomatocyte/splenomegaly represents a special clinical manifestations of phytosterolemia, and distinct changes of blood cell morphology are the typical characters. Plasma plant sterols and ABCG5/ABCG8 genes should be analyzed when such hematologic abnormalities are unexplained.
- The effects of statins on benign prostatic hyperplasia and the lower urinary tract symptoms: A Meta-analysis. [Meta-Analysis]
- MMedicine (Baltimore) 2019; 98(18):e15502
- CONCLUSIONS: Statins have no significant effect on the incidence of BPH, but statins can reduce the risk of BPH for patients over 60 years old. For patients with hyperlipidemia, the duration of medication is more than 1 year, which can slow down the progression of LUTS. However, more high-quality and large sample size studies are needed to further improve and verify.
- Is There a Need to Revise Goals in the Management of Dyslipidemias? [Review]
- CCCurr Cardiol Rep 2019 Apr 30; 21(6):51
- Current guidelines on the management of patients with dyslipidemias recommend specific risk-dependent low-density lipoprotein cholesterol (LDL-C) treatment goals. Recently, several randomized clinica…
Current guidelines on the management of patients with dyslipidemias recommend specific risk-dependent low-density lipoprotein cholesterol (LDL-C) treatment goals. Recently, several randomized clinical trials have investigated further lowering of LDL-C in addition to statin therapy using novel therapeutic approaches and examined their effects on cardiovascular (CV) risk. This review summarizes newly available data on efficacy and safety of lowering LDL-C beyond statin therapy and below current treatment targets.
New Search Next
- Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases. [Journal Article]
- NCNat Commun 2019 04 30; 10(1):1981
- Cardiovascular and metabolic disease (CMD) remains a main cause of premature death worldwide. Berberine (BBR), a lipid-lowering botanic compound with diversified potency against metabolic disorders, …
Cardiovascular and metabolic disease (CMD) remains a main cause of premature death worldwide. Berberine (BBR), a lipid-lowering botanic compound with diversified potency against metabolic disorders, is a promising candidate for ameliorating CMD. The liver is the target of BBR so that liver-site accumulation could be important for fulfilling its therapeutic effect. In this study a rational designed micelle (CTA-Mic) consisting of α-tocopheryl hydrophobic core and on-site detachable polyethylene glycol-thiol shell is developed for effective liver deposition of BBR. The bio-distribution analysis proves that the accumulation of BBR in liver is increased by 248.8% assisted by micelles. Up-regulation of a range of energy-related genes is detectable in the HepG2 cells and in vivo. In the high fat diet-fed mice, BBR-CTA-Mic intervention remarkably improves metabolic profiles and reduces the formation of aortic arch plaque. Our results provide proof-of-concept for a liver-targeting strategy to ameliorate CMD using natural medicines facilitated by Nano-technology.